Holen Sie sich die Stockscreener-App
7.895
1.40%
0.015
Schlusskurs vom Vortag:
$7.88
Offen:
$7.9
24-Stunden-Volumen:
14,905
Relative Volume:
0.34
Marktkapitalisierung:
$18.73M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.85M
KGV:
-25.47
EPS:
-0.31
Netto-Cashflow:
$-3.95M
1W Leistung:
+9.00%
1M Leistung:
-19.86%
6M Leistung:
-38.40%
1J Leistung:
-51.72%
1-Tages-Spanne:
$7.77
$8.12
1-Wochen-Bereich:
$6.55
$8.20
52-Wochen-Spanne:
$6.42
$22.90
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Firmenname
Cadrenal Therapeutics Inc
Sektor
Branche
Telefon
904-300-0701
Adresse
822 A1A NORTH, PONTE VEDRA
Vergleichen Sie CVKD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
8.01 | 18.42M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.37 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.29 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
814.78 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.34 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-18 | Eingeleitet | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Aktie (CVKD) Neueste Nachrichten
Will Cadrenal Therapeutics Inc. stock keep outperforming rivals2025 Key Highlights & Community Verified Watchlist Alerts - ulpravda.ru
Will Cadrenal Therapeutics Inc. stock benefit from commodity pricesWeekly Trend Summary & Real-Time Volume Trigger Notifications - ulpravda.ru
Can Cadrenal Therapeutics Inc. stock deliver consistent earnings growthMarket Performance Summary & Weekly Consistent Profit Watchlists - ulpravda.ru
What sentiment indicators say about Cadrenal Therapeutics Inc. stockMarket Growth Report & Weekly Market Pulse Updates - ulpravda.ru
Risk Analysis: Why Cadrenal Therapeutics Inc. stock remains undervaluedBreakout Watch & Daily Profit Maximizing Tips - ulpravda.ru
How Cadrenal Therapeutics Inc. stock trades during market volatilityJuly 2025 Institutional & Stepwise Trade Execution Plans - ulpravda.ru
Is Cadrenal Therapeutics Inc. stock a contrarian buyTrade Performance Summary & Step-by-Step Swing Trade Plans - ulpravda.ru
Cadrenal Therapeutics acquires VLX-1005 from Veralox - MSN
(CVKD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Matthew Szot Sells 9,933 Shares of Cadrenal Therapeutics (NASDAQ:CVKD) Stock - Defense World
Cadrenal Therapeutics Earnings Notes - Trefis
Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System - The Globe and Mail
How a small biotech is building an emergency anticoagulation plan - Stock Titan
Cadrenal Therapeutics announces new securities purchase agreement - MSN
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On - ACCESS Newswire
Inside the drug startup rebuilding blood thinners for medicine’s toughest cases - Stock Titan
(CVKD) Volatility Zones as Tactical Triggers - Stock Traders Daily
Cadrenal Therapeutics Expands At-The-Market Stock Offering Capacity - The Globe and Mail
Cadrenal Therapeutics Appoints Dr. Golden to Board - MSN
Cadrenal Therapeutics Files Prospectus Supplement for ATM Offering - TradingView — Track All Markets
Cadrenal Therapeutics (NASDAQ:CVKD) & Biodexa Pharmaceuticals (NASDAQ:BDRX) Financial Analysis - Defense World
Downgrade Watch: Will Cadrenal Therapeutics Inc stock benefit from commodity pricesEarnings Beat & Detailed Earnings Play Alerts - moha.gov.vn
Is Cadrenal Therapeutics Inc. stock attractive for long term wealth buildingJuly 2025 Big Picture & Fast Gaining Stock Strategy Reports - ulpravda.ru
How Cadrenal Therapeutics Inc. stock performs in stagflation2025 Support & Resistance & Fast Entry High Yield Stock Tips - Улправда
Is Cadrenal Therapeutics Inc. stock recession proofWeekly Profit Recap & Capital Efficient Trading Techniques - Улправда
Is Cadrenal Therapeutics Inc. stock positioned for digital transformationInsider Buying & Community Verified Trade Signals - Улправда
Can Cadrenal Therapeutics Inc. stock resist market sell offsJuly 2025 Movers & Technical Buy Zone Confirmations - Улправда
Can Cadrenal Therapeutics Inc. stock deliver surprise earnings beatTrade Analysis Summary & Daily Entry Point Trade Alerts - Улправда
Aug PreEarnings: Is Cadrenal Therapeutics Inc. stock a contrarian buy2025 Market Sentiment & Weekly High Momentum Picks - DonanımHaber
Ideas Watch: Is Cadrenal Therapeutics Inc. stock positioned for digital transformationInsider Selling & Weekly Setup with ROI Potential - Улправда
Is Cadrenal Therapeutics Inc. stock affected by interest rate hikesJuly 2025 Opening Moves & Free Real-Time Market Sentiment Alerts - Улправда
How Cadrenal Therapeutics Inc. stock responds to policy changes2025 Bull vs Bear & Expert Curated Trade Setups - Улправда
Will Cadrenal Therapeutics Inc. stock sustain high P E ratiosJuly 2025 Volume & Technical Pattern Based Signals - Улправда
Cadrenal Therapeutics to conduct partnering and investor meetings - marketscreener.com
Cadrenal Therapeutics To Conduct Partnering And Investor Meetings - TradingView — Track All Markets
Cadrenal Therapeutics, Inc. Management to Hold Investor and Partner Meetings at the 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026 - Sahm
Cadrenal Therapeutics to Conduct Partnering and Investor - GlobeNewswire
Cadrenal Therapeutics Announces New Securities Purchase Agreement - TipRanks
Understanding the Setup: (CVKD) and Scalable Risk - Stock Traders Daily
CVKDCadrenal Therape Latest Stock News & Market Updates - Stock Titan
Cadrenal's Quiet Expansion Play Is Starting to Get Loud - guardonline.com
Cadrenal Therapeutics (NASDAQ: CVKD) adds HIT, Factor XIa drugs in quiet expansion - Stock Titan
Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market - Voice of Alexandria
Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox By Investing.com - Investing.com Australia
About Us | Laser Focus WorldCadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market - FinancialContent
Cadrenal Therapeutics acquires late-stage drug assets from Maryland biotech - The Business Journals
Cadrenal Therapeutics acquires VLX-1005 for heparin-induced thrombocytopenia - TipRanks
Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox - Investing.com
Cadrenal Therapeutics Acquires VLX-1005 from Veralox - TipRanks
Finanzdaten der Cadrenal Therapeutics Inc-Aktie (CVKD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):